Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms, is pleased to announce that it has identified a promising coating product for reducing infections associated with central venous catheters (CVCs). This milestone is the result of an intensive internal screening study designed to recognize promising candidates, and ultimately identify a lead candidate for further pre-clinical and clinical development.
